MONROVIA, Calif., July 14 /PRNewswire-FirstCall/ -- STAAR Surgical Company today announced that it will release financial results for the second quarter ended July 3, 2009 on Monday, August 3, 2009 before the market opens. In addition, the Company today reported that cash and cash equivalents and restricted cash as of July 3, 2009 were $13.1 million. This balance includes the proceeds from the registered direct offering of common shares on June 17, 2009 of $8.6 million. Cash and cash equivalents at the close of the first quarter of 2009 on April 3 were $3.7 million.
The Company will host a conference call and webcast on Monday, August 3, 2009 at 8:30 a.m. Eastern / 5:30 a.m. Pacific to discuss the Company’s second quarter results and current corporate developments. The dial-in number for the conference call is 877-941-1848 for domestic participants and 480-629-9722 for international participants.
About STAAR Surgical
STAAR is a leader in the development, manufacture and marketing of minimally invasive ophthalmic products employing proprietary technologies. STAAR’s products are used by ophthalmic surgeons and include the Visian ICL, a tiny, flexible lens implanted to correct refractive errors, as well as innovative products designed to improve patient outcomes for cataracts and glaucoma. Manufactured in Switzerland by STAAR, the ICL is approved by the FDA for use in treating myopia, has received CE Marking and is sold in more than 50 countries. More information is available at http://www.staar.com.
SOURCE STAAR Surgical Company
CONTACT: Investors, Doug Sherk or Mike Pollock, +1-415-896-5862, or Media,
Chris Gale, +1-646-201-5431; all of EVC Group for STAAR Surgical Company
Web site: http://www.staar.com/
